Dengue virus replicons: Production of an interserotypic chimera and cell lines from different species, and establishment of a cell-based fluorescent assay to screen inhibitors, validated by the evaluation of ribavirin's activity

Antiviral Research

Volumn 86, Issue 3, 2010, Pages 296-305

  Massé, Nicolas ^a   Davidson, Andrew ^b   Ferron, François ^a   Alvarez, Karine ^a   Jacobs, Mike ^c   Romette, Jean Louis ^a   Canard, Bruno ^a   Guillemot, Jean Claude ^a  

^a AIX MARSEILLE UNIVERSITY   (France)

^b UNIVERSITY OF BRISTOL   (United Kingdom)

^c ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

Antiviral; Dengue virus; HTS; NS5; Replicon

Indexed keywords

ACYLTRANSFERASE; ENHANCED GREEN FLUORESCENT PROTEIN; NONSTRUCTURAL PROTEIN 5; PUROMYCIN N ACETYLTRANSFERASE; RIBAVIRIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTIVIRAL ACTIVITY; ARTICLE; CELL ASSAY; CELL LINE; CELL STRAIN; CHEMOPROPHYLAXIS; CHIMERA; CONTROLLED STUDY; DENGUE; DENGUE VIRUS 2; DENGUE VIRUS 3; DRUG SCREENING; DRUG TARGETING; FLOW CYTOMETRY; FLUORESCENCE ANALYSIS; GENE CONSTRUCT; GENE EXPRESSION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IN VITRO STUDY; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; REPLICON; REPORTER GENE; RNA TRANSCRIPTION; SEROTYPE; VIRUS REPLICATION; WESTERN BLOTTING;

ANIMALS; ANTIVIRAL AGENTS; CELL LINE; CERCOPITHECUS AETHIOPS; CRICETINAE; DENGUE VIRUS; DRUG EVALUATION, PRECLINICAL; FLOW CYTOMETRY; GENE EXPRESSION; GENES, REPORTER; GREEN FLUORESCENT PROTEINS; HUMANS; MICROBIAL SENSITIVITY TESTS; RECOMBINANT FUSION PROTEINS; RIBAVIRIN; STAINING AND LABELING; VIRAL NONSTRUCTURAL PROTEINS;

DENGUE VIRUS; DENGUE VIRUS TYPE 2; FLAVIVIRUS;

EID: 77952672747     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2010.03.010     Document Type: Article

References (62)

1. Alvarez D.E., Filomatori C.V., Gamarnik A.V. Functional analysis of dengue virus cyclization sequences located at the 5' and 3'UTRs. Virology 2008, 375:223-235.
2. Alvarez D.E., Lodeiro M.F., Ludueña S.J., Pietrasanta L.I., Gamarnik A.V. Long-range RNA-RNA interactions circularize the dengue virus genome. J. Virol. 2005, 79:6631-6643.
3. Benarroch D., Egloff M.P., Mulard L., Guerreiro C., Romette J.L., Canard B. A structural basis for the inhibition of the NS5 dengue virus mRNA 2'-O-methyltransferase domain by ribavirin 5'-triphosphate. J. Biol. Chem. 2004, 279:35638-35643.
4. Crance J.M., Scaramozzino N., Jouan A., Garin D. Interferon, ribavirin, 6-azauridine and glycyrrhizin: antiviral compounds active against pathogenic F flaviviruses. Antiviral Res. 2003, 58:73-79.
5. de Felipe P., Luke G.A., Hughes L.E., Gani D., Halpin C., Ryan M.D. E unum pluribus: multiple proteins from a self-processing polyprotein. Trends Biotechnol. 2006, 24:68-75.
6. Dong H., Zhang B., Shi P.Y. Flavivirus methyltransferase: A novel antiviral target. Antiviral Res. 2008, 80:1-10.
7. Doronina V.A., Wu C., de Felipe P., Sachs M.S., Ryan M.D., Brown J.D. Site-specific release of nascent chains from ribosomes at a sense codon. Mol. Cell. Biol. 2008, 28:4227-4239.
8. Egloff M.P., Benarroch D., Selisko B., Romette J.L., Canard B. An RNA cap (nucleoside-2'-O-)-methyltransferase in the flavivirus RNA polymerase NS5: crystal structure and functional characterization. EMBO J. 2002, 21:2757-2768.
9. Ekkapongpisit M., Wannatung T., Susantad T., Triwitayakorn K., Smith D.R. cDNA-AFLP analysis of differential gene expression in human hepatoma cells (HepG2) upon dengue virus infection. J. Med. Virol. 2007, 79:552-561.
10. Falgout B., Chanock R., Lai C.J. Proper processing of dengue virus nonstructural glycoprotein NS1 requires the N-terminal hydrophobic signal sequence and the downstream nonstructural protein NS2a. J. Virol. 1989, 63:1852-1860.
11. Fayzulin R., Scholle F., Petrakova O., Frolov I., Mason P.W. Evaluation of replicative capacity and genetic stability of West Nile virus replicons using highly efficient packaging cell lines. Virology 2006, 351:196-209.
12. Filomatori C.V., Lodeiro M.F., Alvarez D.E., Samsa M.M., Pietrasanta L., Gamarnik A.V. A 5' RNA element promotes dengue virus RNA synthesis on a circular genome. Genes Dev. 2006, 20:2238-2249.
13. Goodell J.R., Puig-Basagoiti F., Forshey B.M., Shi P.Y., Ferguson D.M. Identification of compounds with anti-West Nile Virus activity. J. Med. Chem. 2006, 49:2127-2137.
14. Graci J.D., Cameron C.E. Mechanisms of action of ribavirin against distinct viruses. Rev. Med. Virol. 2006, 16:37-48.
15. Gu B., Ouzunov S., Wang L., Mason P., Bourne N., Cuconati A., Block T.M. Discovery of small molecule inhibitors of West Nile virus using a high-throughput sub-genomic replicon screen. Antiviral Res. 2006, 70:39-50.
16. Gualano R.C., Pryor M.J., Cauchi M.R., Wright P.J., Davidson A.D. Identification of a major determinant of mouse neurovirulence of dengue virus type 2 using stably cloned genomic-length cDNA. J. Gen. Virol. 1998, 79:437-446.
17. Harvey T.J., Liu W.J., Wang X.J., Linedale R., Jacobs M., Davidson A., Le T.T., Anraku I., Suhrbier A., Shi P.Y., Khromykh A.A. Tetracycline-inducible packaging cell line for production of flavivirus replicon particles. J. Virol. 2004, 78:531-538.
18. Hellen C.U., Sarnow P. Internal ribosome entry sites in eukaryotic mRNA molecules. Genes Dev. 2001, 15:1593-1612.
19. Hennecke M., Kwissa M., Metzger K., Oumard A., Kröger A., Schirmbeck R., Reimann J., Hauser H. Composition and arrangement of genes define the strength of IRES-driven translation in bicistronic mRNAs. Nucleic Acids Res. 2001, 29:3327-3334.
20. Hershkovitz O., Zilka A., Bar-Ilan A., Abutbul S., Davidson A., Mazzon M., Kümmerer B.M., Monsoengo A., Jacobs M., Porgador A. Dengue virus replicon expressing the nonstructural proteins suffices to enhance membrane expression of HLA class I and inhibit lysis by human NK cells. J. Virol. 2008, 82:7666-7676.
21. Higa L.M., Caruso M.B., Canellas F., Soares M.R., Oliveira-Carvalho A.L., Chapeaurouge D.A., Almeida P.M., Perales J., Zingali R.B., Da Poian A.T. Secretome of HepG2 cells infected with dengue virus: implications for pathogenesis. Biochim. Biophys. Acta 2008, 1784:1607-1616.
22. Huerre M.R., Lan N.T., Marianneau P., Hue N.B., Khun H., Hung N.T., Khen N.T., Drouet M.T., Huong V.T., Ha D.Q., Buisson Y., Deubel V. Liver histopathology and biological correlates in five cases of fatal dengue fever in Vietnamese children. Virchows Arch. 2001, 438:107-115.
23. Ibrahimi A., Vande Velde G., Reumers V., Toelen J., Thiry I., Vandeputte C., Vets S., Deroose C., Bormans G., Baekelandt V., Debyser Z., Gijsbers R. Highly efficient multicistronic lentiviral vectors with peptide 2A sequences. Hum. Gene Ther. 2009, 20:845-860.
24. Johnston P.A., Phillips J., Shun T.Y., Shinde S., Lazo J.S., Huryn D.M., Myers M.C., Ratnikov B.I., Smith J.W., Su Y., Dahl R., Cosford N.D., Shiryaev S.A., Strongin A.Y. HTS identifies novel and specific uncompetitive inhibitors of the two-component NS2B-NS3 proteinase of West Nile virus. Assay Drug Dev. Technol. 2007, 5:737-750.
25. Jones M., Davidson A., Hibbert L., Gruenwald P., Schlaak J., Ball S., Foster G.R., Jacobs M. Dengue virus inhibits alpha interferon signaling by reducing STAT2 expression. J. Virol. 2005, 79:5414-5420.
26. Kapoor M., Zhang L., Ramachandra M., Kusukawa J., Ebner K.E., Padmanabhan R. Association between NS3 and NS5 proteins of dengue virus type 2 in the putative RNA replicase is linked to differential phosphorylation of NS5. J. Biol. Chem. 1995, 270:19100-19106.
27. Khromykh A.A., Meka H., Guyatt K.J., Westaway E.G. Essential role of cyclization sequences in flavivirus RNA replication. J. Virol. 2001, 75:6719-6728.
28. Koff W.C., Elm J.L., Halstead S.B. Antiviral effects if ribavirin and 6-mercapto-9-tetrahydro-2-furylpurine against dengue viruses in vitro. Antiviral Res. 1982, 2:69-79.
29. Lescar J., Luo D., Xu T., Sampath A., Lim S.P., Canard B., Vasudevan S.G. Towards the design of antiviral inhibitors against flaviviruses: the case for the multifunctional NS3 protein from Dengue virus as a target. Antiviral Res. 2008, 80:94-101.
30. Leung J.Y., Pijlman G.P., Kondratieva N., Hyde J., Mackenzie J.M., Khromykh A.A. Role of nonstructural protein NS2A in flavivirus assembly. J. Virol. 2008, 82:4731-4741.
31. Liang C., Rieder E., Hahm B., Jang S.K., Paul A., Wimmer E. Replication of a novel subgenomic HCV genotype 1a replicon expressing a puromycin resistance gene in Huh-7 cells. Virology 2005, 333:41-53.
32. Lim S.P., Wen D., Yap T.L., Yan C.K., Lescar J., Vasudevan S.G. A scintillation proximity assay for dengue virus NS5 2'-O-methyltransferase-kinetic and inhibition analyses. Antiviral Res. 2008, 80:360-369.
33. Lindenbach B.D., Thiel H.J., Rice C.M. Flaviviridae: the viruses and their replication. Fields Virology, Vol. 1 2007, 1101-1152. Lippincott Williams & Wilkins. D.M. Knipe, P.M. Howley (Eds.).
34. Liu W.J., Wang X.J., Mokhonov V.V., Shi P.Y., Randall R., Khromykh A.A. Inhibition of interferon signaling by the New York 99 strain and Kunjin subtype of West Nile virus involves blockage of STAT1 and STAT2 activation by nonstructural proteins. J. Virol. 2005, 79:1934-1942.
35. Lo M.K., Tilgner M., Bernard K.A., Shi P.Y. Functional analysis of mosquito-borne flavivirus conserved sequence elements within 3' untranslated region of West Nile virus by use of a reporting replicon that differentiates between viral translation and RNA replication. J. Virol. 2003, 77:10004-10014.
36. Lo M.K., Tilgner M., Shi P.Y. Potential high-throughput assay for screening inhibitors of West Nile virus replication. J. Virol. 2003, 77:12901-12906.
37. Malet H., Massé N., Selisko B., Romette J.L., Alvarez K., Guillemot J.C., Tolou H., Yap T.L., Vasudevan S., Lescar J., Canard B. The flavivirus polymerase as a target for drug discovery. Antiviral Res. 2008, 80:23-35.
38. Mizuguchi H., Xu Z., Ishii-Watabe A., Uchida E., Hayakawa T. IRES-dependent second gene expression is significantly lower than cap-dependent first gene expression in a bicistronic vector. Mol. Ther. 2000, 1:376-382.
39. Ng C.Y., Gu F., Phong W.Y., Chen Y.L., Lim S.P., Davidson A., Vasudevan S.G. Construction and characterization of a stable subgenomic dengue virus type 2 replicon system for antiviral compound and siRNA testing. Antiviral Res. 2007, 76:222-231.
40. Noueiry A.O., Olivo P.D., Slomczynska U., Zhou Y., Buscher B., Geiss B., Engle M., Roth R.M., Chung K.M., Samuel M., Diamond M.S. Identification of novel small-molecule inhibitors of West Nile virus infection. J. Virol. 2007, 81:11992-12004.
41. Parker W.B. Metabolism and antiviral activity of ribavirin. Virus Res. 2005, 107:165-171.
42. Pattanakitsakul S.N., Rungrojcharoenkit K., Kanlaya R., Sinchaikul S., Noisakran S., Chen S.T., Malasit P., Thongboonkerd V. Proteomic analysis of host responses in HepG2 cells during dengue virus infection. J. Proteome Res. 2007, 6:4592-4600.
43. Pryor M.J., Carr J.M., Hocking H., Davidson A.D., Li P., Wright P.J. Replication of dengue virus type 2 in human monocyte-derived macrophages: comparisons of isolates and recombinant viruses with substitutions at amino acid 390 in the envelope glycoprotein. Am. J. Trop. Med. Hyg. 2001, 65:427-434.
44. Puig-Basagoiti F., Deas T.S., Ren P., Tilgner M., Ferguson D.M., Shi P.Y. High-throughput assays using a luciferase-expressing replicon, virus-like particles, and full-length virus for West Nile virus drug discovery. Antimicrob. Agents Chemother. 2005, 49:4980-4988.
45. Puig-Basagoiti F., Qing M., Dong H., Zhang B., Zou G., Yuan Z., Shi P.Y. Identification and characterization of inhibitors of West Nile virus. Antiviral Res. 2009, 83:71-79.
46. Puig-Basagoiti F., Tilgner M., Forshey B.M., Philpott S.M., Espina N.G., Wentworth D.E., Goebel S.J., Masters P.S., Falgout B., Ren P., Ferguson D.M., Shi P.Y. Triaryl pyrazoline compound inhibits flavivirus RNA replication. Antimicrob. Agents Chemother. 2006, 50:1320-1329.
47. Rice C.M., Lenches E.M., Eddy S.R., Shin S.J., Sheets R.L., Strauss J.H. Nucleotide sequence of yellow fever virus: implications for flavivirus gene expression and evolution. Science 1985, 229:726-733.
48. Rodrigo W.W., Jin X., Blackley S.D., Rose R.C., Schlesinger J.J. Differential enhancement of dengue virus immune complex infectivity mediated by signaling-competent and signaling-incompetent human Fcgamma RIA (CD64) or FcgammaRIIA (CD32). J. Virol. 2006, 80:10128-10138.
49. Rossi S.L., Fayzulin R., Dewsbury N., Bourne N., Mason P.W. Mutations in West Nile virus nonstructural proteins that facilitate replicon persistence in vitro attenuate virus replication in vitro and in vivo. Virology 2007, 364:184-195.
50. Rossi S.L., Zhao Q., O'Donnell V.K., Mason P.W. Adaptation of West Nile virus replicons to cells in culture and use of replicon-bearing cells to probe antiviral action. Virology 2005, 331:457-470.
51. Selisko B., Dutartre H., Guillemot J.C., Debarnot C., Benarroch D., Khromykh A., Desprès P., Egloff M.P., Canard B. Comparative mechanistic studies of de novo RNA synthesis by flavivirus RNA-dependent RNA polymerases. Virology 2006, 351:145-158.
52. Seneviratne S.L., Malavige G.N., de Silva H.J. Pathogenesis of liver involvement during dengue viral infections. Trans. R. Soc. Trop. Med. Hyg. 2006, 100:608-614.
53. Shi P.Y., Tilgner M., Lo M.K. Construction and characterization of subgenomic replicons of New York strain of West Nile virus. Virology 2002, 296:219-233.
54. Sidwell R.W., Huffman J.H., Khare G.P., Allen L.B., Witkowski J.T., Robins R.K. Broad-spectrum antiviral activity of Virazole: 1-beta-D-ribofuranosyl-1,2,4-triazole-3-carboxamide. Science 1972, 177:705-706.
55. Streeter D.G., Witkowski J.T., Khare G.P., Sidwell R.W., Bauer R.J., Robins R.K., Simon L.N. Mechanism of action of 1- -D-ribofuranosyl-1,2,4-triazole-3-carboxamide (Virazole), a new broad-spectrum antiviral agent. Proc. Natl. Acad. Sci. U.S.A. 1973, 70:1174-1178.
56. Suzuki R., de Borba L., Duarte dos Santos C.N., Mason P.W. Construction of an infectious cDNA clone for a Brazilian prototype strain of dengue virus type 1: characterization of a temperature-sensitive mutation in NS1. Virology 2007, 362:374-383.
57. Takhampunya R., Ubol S., Houng H.S., Cameron C.E., Padmanabhan R. Inhibition of dengue virus replication by mycophenolic acid and ribavirin. J. Gen. Virol. 2006, 87:1947-1952.
58. Tilgner M., Deas T.S., Shi P.Y. The flavivirus-conserved penta-nucleotide in the 3' stem-loop of the West Nile virus genome requires a specific sequence and structure for RNA synthesis, but not for viral translation. Virology 2005, 331:375-386.
59. Tilgner M., Shi P.Y. Structure and function of the 3' terminal six nucleotides of the west nile virus genome in viral replication. J. Virol. 2004, 78:8159-8171.
60. Yap T.L., Xu T., Chen Y.L., Malet H., Egloff M.P., Canard B., Vasudevan S.G., Lescar J. Crystal structure of the dengue virus RNA-dependent RNA polymerase catalytic domain at 1.85-angstrom resolution. J. Virol. 2007, 81:4753-4765.
61. You S., Padmanabhan R. A novel in vitro replication system for Dengue virus. Initiation of RNA synthesis at the 3'-end of exogenous viral RNA templates requires 5'- and 3'-terminal complementary sequence motifs of the viral RNA. J. Biol. Chem. 1999, 274:33714-33722.
62. Zhang J.H., Chung T.D., Oldenburg K.R. A simple statistical parameter for use in evaluation and validation of high throughput screening assays. J. Biomol. Screen. 1999, 4:67-73.